.png){kind=icon}
.png){kind=icon}
Return
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
.png){kind=icon}
OA
AI
F
R
M
M
D
N
N
A
A
P
S
M
M
R
S
R
E
DOI：10.1016/j.jlr.2026.101063.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.1
Papers:
5.8K
Citations:
2.4W
Organization
No organization information available
Cited Papers